Emyria Ltd has released a press release.
Emyria adds wearables to psychedelic-assisted therapy trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Pause in Trading
- Positive animal data for Emyrias ultra-pure CBD capsule
- Positive initial MDMA-analogue screening results
- Emyria receives $1,162,000 R&D Tax Incentive Refund
- Emyria Welcomes Tattarang as Strategic Investor
Later from Emyria
- Notification regarding unquoted securities - EMD
- Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
- Application for quotation of securities - EMD
- Emyria grows its novel MDMA-analogue library
- Ethics approval received for EMD-RX5 Phase 1 Study
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria